Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
36.76
-0.81 (-2.16%)
At close: Jul 19, 2024, 4:00 PM
36.77
+0.01 (0.03%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 160 employees as of December 31, 2023. The number of employees increased by 12 or 8.11% compared to the previous year.
Employees
160
Change (1Y)
12
Growth (1Y)
8.11%
Revenue / Employee
$37,950
Profits / Employee
-$905,475
Market Cap
2.42B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 160 | 12 | 8.11% |
Dec 31, 2022 | 148 | 14 | 10.45% |
Dec 31, 2021 | 134 | 9 | 7.20% |
Dec 31, 2020 | 125 | -5 | -3.85% |
Dec 31, 2019 | 130 | -7 | -5.11% |
Dec 31, 2018 | 137 | -60 | -30.46% |
Dec 31, 2017 | 197 | -13 | -6.19% |
Dec 31, 2016 | 210 | 11 | 5.53% |
Dec 31, 2015 | 199 | 38 | 23.60% |
Dec 31, 2014 | 161 | 32 | 24.81% |
Dec 31, 2013 | 129 | 17 | 15.18% |
Dec 31, 2012 | 112 | 9 | 8.74% |
Dec 31, 2011 | 103 | 3 | 3.00% |
Dec 31, 2010 | 100 | 7 | 7.53% |
Dec 31, 2009 | 93 | 12 | 14.81% |
Dec 31, 2008 | 81 | 28 | 52.83% |
Dec 31, 2007 | 53 | -33 | -38.37% |
Dec 31, 2006 | 86 | 13 | 17.81% |
Dec 31, 2005 | 73 | 11 | 17.74% |
Dec 31, 2004 | 62 | 3 | 5.08% |
Dec 31, 2003 | 59 | -7 | -10.61% |
Dec 31, 2002 | 66 | -5 | -7.04% |
Dec 31, 2001 | 71 | 5 | 7.58% |
Dec 31, 2000 | 66 | 16 | 32.00% |
Dec 31, 1999 | 50 | -3 | -5.66% |
Dec 31, 1998 | 53 | 17 | 47.22% |
Dec 31, 1997 | 36 | -7 | -16.28% |
Dec 31, 1996 | 43 | -14 | -24.56% |
Dec 31, 1995 | 57 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Ardent Health Partners | 23,000 |
Fortrea Holdings | 19,000 |
Integra LifeSciences Holdings | 3,946 |
UFP Technologies | 3,093 |
Myriad Genetics | 2,700 |
Astrana Health | 1,800 |
PTC Therapeutics | 995 |
Intellia Therapeutics | 526 |
CLDX News
- 6 days ago - Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria - GlobeNewsWire
- 6 weeks ago - Celldex Therapeutics to Present at Jefferies Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 - GlobeNewsWire
- 2 months ago - Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis - GlobeNewsWire
- 2 months ago - Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria - GlobeNewsWire
- 4 months ago - Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference - GlobeNewsWire
- 4 months ago - Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference - GlobeNewsWire